Who we work with

C4X Discovery operates a hybrid business model of a wholly owned pipeline of discovery programmes plus partnerships with global and international companies, from top 10 pharma through to biotech.

The Company is partnered with the Structural Genomic Consortium to assist with the identification and validation of new drug targets and has several active research collaborations with academic institutions.

Indivior

The world leader in addiction treatment
The world leader in addiction treatment with over 20 years of experience and a patient-focused approach. Their endeavor started small, with one singular focus – to intimately understand the journey of individuals suffering with addiction. People with addiction are often stereotyped and discounted, creating an environment where many are under-diagnosed, undertreated and under-supported.

LifeArc

Pioneering new ways to turn great science into greater patient impact
LifeArc is a medical research charity with a 25-year legacy of helping scientists and organisations turn their research into treatments and diagnostics for patients. LifeArc turns great science into greater patient impact. The charity brings together a network of partners to tackle specific diseases and directly funds academic and early stage research.

GTN

A disruptive new player in the field of drug discovery artificial intelligence (“AI”)
GTN have already demonstrated state-of-the-art prediction of molecular characterisation. This is a critical step in the hunt for new drugs outside of the crowded space being mined by more traditional methods. GTN are currently running collaborations with global pharmaceutical companies, with a number of the ten largest pharmaceutical companies in our pipeline, and have strong partnerships with world-leading research bodies including the Francis Crick Institute.

Horizon Discovery Ltd

A global leader in the application of gene editing and gene modulation technologies
A fully integrated Life Science company that provides enabling products, services and research programs to clients engaged at every stage of the healthcare continuum from sequence to treatment.

e-therapeutics

The network-driven drug discovery (NDD) company
e-theraupeutics are an Oxford, UK-based business with a revolutionary computer-based platform and a unique network-driven drug discovery ("NDD") methodology which allows us to discover novel and better drugs faster.

AstraZeneca

Global top 10 Pharma
AstraZeneca in the UK has a focus on developing new medicines that make a meaningful difference to patients’ lives. AstraZeneca is a major contributor to UK science and innovation investment, economic prosperity and to patient health.

Evotec

Largest European CRO
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. They operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation.

SGC-Oxford

Structural Genomic Consortium
The SGC is a world leader in public-private partnership that supports the discovery of new medicines through open access research. The SGC is backed by the Welcome Trust and major pharma including Bayer, Pfizer, Abbvie, Merck, J&J, Boehringer Ingelheim, Novartis and Takeda.

Research Collaborations